Biology Reference
In-Depth Information
cis-diaminedichloroplatinum(II) independent of p53 status.
Clin
Cancer Res
1997;
3
:2087
144. Dickey JS, Redon CE, Nakamura AJ, et al. H2AX: functional roles
and potential applications.
Chromosoma
2009;
118
:683
92.
145. Bonner WM, Redon CE, Dickey JS, et al.
g
H2AX and cancer.
Nat
Rev Cancer
2008;
8
:957
97.
135. Hirose Y, Berger MS, Pieper RO. Abrogation of the Chk1-mediated
(G2) checkpoint pathway potentiates temozolominde-induced
toxicity in a p53-independent manner in human glioblastoma
cells.
Cancer Res
2001;
61
:5843
e
e
67.
146. Rogakou EP, Boon C, Redon C, Bonner WM. Megabase chromatin
domains involved in DNA double-strand breaks in vivo.
J Cell
Biol
1999;
146
:905
e
9.
136. Tse AN, Schwarz GK. Potentiation of cytotoxicity of top-
oisomerase I poison by concurrent and sequential treatment with
the checkpoint kinase inhibitor UCN-01 involves disparate
mechanisms resulting in either p53-independent clonogenic
suppression or p53-dependent mitotic catastrophe.
Cancer Res
2004;
64
:6635
e
16.
147. Sedelnikova OA, Rogakou EP, Panyutin IG, Bonner WM. Quan-
titative detection of (125)IdU-induced DNA double-strand breaks
with gamma-H2AX antibody.
Radiat Res
2002;
158
:486
e
92.
148. Ayoub N, Jeyasekharan AD, Bernal JA, Venkitaraman AR. HP1-
beta mobilization promotes chromatin changes that initiate the
DNA damage response.
Nature
2008;
453
:682
e
44.
137. Han H, Bearss DJ, Browne LW, et al. Identification of differen-
tially expressed genes in pancreatic cancer cells using cDNA
microarray.
Cancer Res
2002;
62
:2890
e
6.
149. Syljuasen RG, Sorensen CS, Nylandsted J, et al. Inhibition of Chk1
by CEP-3891 accelerates mitotic nuclear fragmentation in
response to ionizing radiation.
Cancer Res
2004;
64
:9035
e
6.
138. Vispe S, Cazaux C, Lesca C, Defais M. Overexpression of Rad51
protein stimulates homologous recombination and increases
resistance of mammalian cells to ionizing radiation.
Nucleic Acids
Res
1998;
26
:2859
e
40.
150. Ashwell S. Strategies towards more effective anticancer therapies:
targeting DNA damage response pathways.
Expert Rev Clin
Pharmacol
2010;
3
:103
e
15.
151. Leung-Pineda V, Ryan CE, Piwnica-Worms H. Phosphorylation of
Chk1 by ATR is antagonized by a Chk1-regulated protein phos-
phatase 2A circuit.
Mol Cell Biol
2006;
26
:7529
e
64.
139. Maitra A, Kern SE, Hruban RH. Molecular pathogenesis of
pancreatic cancer.
Best Pract Res Clin Gastroenterol
2006;
20
:211
e
26.
140. Maacke H, Jost K, Opitz S, et al. DNA repair and recombination
factor Rad51 is over-expressed in human pancreatic adenocarci-
noma.
Oncogene
2000;
19
:2791
e
38.
152. Hirai H, Arai T, Okada M, et al. MK-1775, a small molecule Wee1
inhibitor, enhances anti-tumor efficacy of various DNA-damag-
ing agents,
e
5.
141. Zabludoff SD, Zhu AC, Deng C,
et al
. Olaparib (AZD2281; PARP
inhibitor) and AZD7762 (CHK inhibitor) act synergistically to
enhance cell death and reduce tumor growth in preclinical
models. Presented at 2009 AACR Annual Meeting, Denver, USA,
18
e
including 5-fluorouracil.
Cancer Biol Ther
2010;
9
:
22.
153. Mizuarai S, Yamanaka K, Itadani H, et al. Discovery of gene
expression based pharmacodynamic biomarker for a p53 context-
specific anti-tumor drug Wee1 inhibitor.
Mol Cancer
2009;
8
:34
514
e
45.
154. Maya-Mendoza A, Petermann E, Gillespie DA, Caldecott KW,
Jackson DA. Chk1 regulates the density of active replication
origins during the vertebrate S phase.
EMBO J
2007;
26
:2719
e
22 April 2009, Abst 2487.
142. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways
regulate phosphorylation and activation of human Chk1.
Mol Cell
Biol
2001;
21
:4129
e
31.
155. Stracker TH, Usui T, Petrini JH. Taking the time to make
important decisions: the checkpoint effector kinases Chk1 and
Chk2 and the DNA damage response.
DNA Repair (Amst)
2009;
8
:1047
e
39.
143. Mah LJ, El-Osta A, Karagiannis TC.
g
H2AX: a sensitive
molecular marker of DNA damage and repair.
Leukemia
2010;
24
:
679
e
86.
54.
e
e
